CD19 and acute lymphoblastic leukemia: There is also a risk of developing resistance to CART therapy in response to prolonged exposure to the modified cells especially in patients with relapse of ALL with negative expression of CD19 or with splice variant of CD19 without exon 2 that is recognized by scFv of CAR-T cells (Jacoby et al. 2018).